drugset / Trial / NCT04020003

A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics

NCT04020003

Phase 3 Unknown 120 enrolled Shenzhen Second People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the curative effect of Levosimendan on ARDS patients through omni-directional and multi-angle objective quantitative indexes, and to study the responsiveness of ARDS with or without right ventricular insufficiency to the treatment of Levosimendan, and to indirectly confirm whether Levosimendan had lung protective mechanism other than calcium sensitization to ARDS patients, such as inhibiting inflammatory reaction to reduce pulmonary capillary leakage and alveolar epithelial cell injury. Relaxation of bronchial smooth muscle improves pulmonary ventilation function. To provide new methods and ideas for clinical treatment of ARDS.

Timeline

Start
2019-07-01
Primary completion
2021-12-30
Completion
2022-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified 12.5 mg